

1 **COVID-19 diagnosis and study of serum SARS-CoV-2 specific IgA, IgM and IgG**
2 **by chemiluminescence immunoanalysis**

3

4 Huan Ma^{1,2#}, Weihong Zeng^{1,2#}, Hongliang He^{3#}, Dan Zhao², Yunru Yang², Dehua Jiang⁴, Peigen
5 Yingjie Qi³, Weihuang He⁴, Changcheng Zhao³, Ruting Yi⁴, Xiaofang Wang⁶, Bo Wang⁷, Yuanhong
6 Yun Yang³, Arnaud John Kombe Kombe², Chengchao Ding⁶, Jiajia Xie⁸, Yong Gao³, Linzhao Cheng¹⁰,
7 Yajuan Li^{7*}, Xiaoling Ma^{11*}, Tengchuan Jin^{1,2,12*}

8

9 ¹Department of Obstetrics and Gynecology, The First Affiliated Hospital of USTC, Division of Life
10 Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui 230001, China

11 ²Hefei National Laboratory for Physical Sciences at Microscale, Laboratory of Structural Immunology,
12 CAS Key Laboratory of Innate Immunity and Chronic Disease, Division of Life Sciences and Medicine,
13 University of Science and Technology of China, Hefei, Anhui 230027, China

14 ³Department of Infectious Diseases, The First Affiliated Hospital of USTC, Division of Life Sciences
15 and Medicine, University of Science and Technology of China, Hefei, Anhui 230001, China

16 ⁴Kangrun Biotech LTD, Guangzhou, Guangdong 511400, China

17 ⁵Department of Statistics, University of Wisconsin-Madison, Madison, WI 53706, USA

18 ⁶The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science
19 and Technology of China, Hefei, Anhui 230001, China

20 ⁷Department of Clinical Laboratory, The First Affiliated Hospital of Anhui Medical University, Hefei
21 230032, China

22 ⁸Department of Dermatology, The First Affiliated Hospital of USTC, Division of Life Sciences and
23 Medicine, University of Science and Technology of China, Hefei, Anhui 230001, China

24 ⁹Institute of Public Health, Division of Life Sciences and Medicine, University of Science and
25 Technology of China, Hefei Anhui 230026, China

26 ¹⁰Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei
27 Anhui 230026, China, and Johns Hopkins University School of Medicine, Columbia, MD USA

28 ¹¹Department of Laboratory Medicine, The First Affiliated Hospital of USTC, Division of Life
29 Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui 230001, China

30 ¹²CAS Center for Excellence in Molecular Cell Science, Chinese Academy of Science, Shanghai
31 200031, China

32

33 [#]These authors contributed equally to this work.

34 ^{*}These authors contributed equally to this work.

35 **Summary:**

36 Chemiluminescence immunoanalysis of SARS-CoV-2 RBD-specific serum IgA as well as IgM and
37 IgG improves accuracy of COVID-19 diagnosis. Concentration kinetics of serum RBD-specific IgA,
38 IgM and IgG are revealed. Serum IgA levels positively correlate with COVID-19 severity.

39

40 Abstract

41 **Background.** The pandemic of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
42 is causing great loss. Detecting viral RNAs is standard approach for SARS-CoV-2 diagnosis with
43 variable success. Currently, studies describing the serological diagnostic methods are emerging, while
44 most of them just involve the detection of SARS-CoV-2-specific IgM and IgG by ELISA or “flow
45 immunoassay” with limited accuracy.

46 **Methods.** Diagnostic approach depends on chemiluminescence immunoanalysis (CLIA) for detecting
47 IgA, IgM and IgG specific to SARS-CoV-2 nucleocapsid protein (NP) and receptor-binding domain
48 (RBD) was developed. The approach was tested with 216 sera from 87 COVID-19 patients and 483
49 sera from SARS-CoV-2 negative individuals. The diagnostic accuracy was evaluated by receiver
50 operating characteristic (ROC) analysis. Concentration kinetics of RBD-specific serum antibodies were
51 characterized. The relationship of serum RBD-specific antibodies and disease severity was analyzed.

52 **Results.** The diagnostic accuracy based on RBD outperformed those based on NP. Adding IgA to a
53 conventional serological test containing IgM and IgG improves sensitivity of SARS-CoV-2 diagnosis
54 at early stage. CLIA for detecting RBD-specific IgA, IgM and IgG showed diagnostic sensitivities of
55 98.6%, 96.8% and 96.8%, and specificities of 98.1%, 92.3% and 99.8%, respectively. Median
56 concentration of IgA and IgM peaked during 16-20 days after illness onset at 8.84 µg/mL and 7.25
57 µg/mL, respectively, while IgG peaked during 21-25 days after illness onset at 16.47 µg/mL.
58 Furthermore, the serum IgA level positively correlates with COVID-19 severity.

59 **Conclusion.** CLIA for detecting SARS-CoV-2 RBD-specific IgA, IgM and IgG in blood provides
60 additional values for diagnosing and monitoring of COVID-19.

61 **Key words:** SARS-CoV-2; IgA; diagnosis; serological test; chemiluminescence

62

63 Introduction

64 At the end of 2019, a novel coronavirus (2019-nCoV or SARS-CoV-2) emerged in Wuhan, Hubei
65 Province in China, causing a new type of coronavirus disease now named as COVID-19[1]. The virus
66 spread globally and became a public health emergency and pandemic declared by the World Health
67 Organization[2]. Among the seven coronaviruses known to cause human diseases, the severe acute
68 respiratory syndrome (SARS) virus broke out in 2003[3] and Middle East Respiratory Syndrome
69 (MERS) virus in 2012[4], COVID-19 is pathologically similar to but different from SARS and MERS
70 is expected to cause great impact on human society since World War II[5]. Reliable and effective
71 diagnosis of SARS-CoV-2 and treatment of COVID-19 are urgently needed.

72 Detection of SARS-CoV-2 viral RNA by methods such as RT-qPCR supplemented by chest CT
73 imaging is the primary method for clinical diagnosis of COVID-19[6, 7]. However, the difficulty to
74 obtain high-quality and consistent throat or nasal swab samples, and the low viral load at the late stage
75 of infection, both challenges resulted in a sensitivity below 70%[8-12]. Therefore, there is an urgent
76 need for more reliable and rapid diagnostic approach to screen SARS-CoV-2 infected people including
77 those who do not have overt symptoms. A serological test of virus-induced antibody production has
78 unique advantages in clinical diagnostics, especially for identifying people who acquired immunity
79 against pathogens without noticeable symptoms[13]. When the virus invades host, the body produces
80 large amounts of immunoglobulin (Ig) by the immune system and releases them into blood, including
81 IgG, IgM and IgA[14]. It is known that IgM is normally the first antibody to be produced in response to

82 the virus invasion[14]. IgG is a major class of immunoglobulins found in the blood, comprising 75% of
83 total serum immunoglobulins and has long-term immunity and immunological memory[14, 15].
84 Therefore, measuring the viral antigen-specific of IgM and IgG in combination has been used in
85 various serological tests for detecting SARS-CoV-2 infection as previously used for SARS and other
86 coronaviruses[9, 10, 13, 16-20]. In contrast, IgA that is mainly produced in mucosal tissues to stop
87 virus invasion and replication but also present in blood (~15% of total immunoglobulins in blood)[21],
88 has not been widely used in serological tests for detecting coronavirus infection. IgA kinetics and roles
89 in anti-viral immunity are even less known. Currently, only a few published studies reported diagnosis
90 of COVID-19 by using ELISA or “flow immunoassay” for detection of serum IgM and IgG with
91 limited accuracy[9, 10, 16-19]. Although detection of SARS-CoV-2 specific IgA in serum was reported
92 in recent papers or a preprint[11, 22, 23], The kinetics of antibody responses in COVID-19 remains
93 undefined, specifically for IgA production.

94 In this investigation, SARS-CoV-2 specific IgA as well as IgM and IgG in 216 sera from 87
95 COVID-19 patients and 483 negative sera were evaluated using chemiluminescence immuno-analysis
96 (CLIA), we demonstrated that the approach based on CLIA of SARS-CoV-2 RBD antibodies have
97 improved diagnostic sensitivity and specificity. Kinetics of each antibody isotype and relationship of
98 serum antibodies and disease severity were also revealed.

99

100 **Methods**

101 **Patients and clinical samples**

102 This study was approved by the Medical Ethical Committee of the First Affiliated Hospital of USTC
103 and the First Affiliated Hospital of Anhui Medical University. Patient information is listed in
104 **supplementary Table 1** with a detailed description. Patient classification was defined according to the
105 New Coronavirus Pneumonia Prevention and Control Program (7th edition) published by the National
106 Health Commission of China. This study enrolls a total of 87 cases of RT-qPCR confirmed COVID-19
107 patients, who were admitted to the First Affiliated Hospital of USTC Hospital or the First Affiliated
108 Hospital of Anhui Medical University between Jan 26 and Mar 5, 2020. Their blood samples were
109 collected during routine clinical testing. For all information of the enrolled patients were obtained from
110 the clinical records.

111 Sera as negative controls were collected in order to evaluate the diagnostic accuracy. This cohort
112 contains 330 archived sera from healthy donors (samples collected before October 2019), 138
113 interfering sera from no-COVID-19 patients with different underlying diseases, and fifteen sera from
114 once suspected cases (RT-qPCR negative but had typical manifestation of pneumonia). All sera were
115 stored at -20 °C before use.

116

117 **Molecular cloning, protein expression and purification**

118 Briefly, the viral nucleocapsid protein (NP) was expressed using *E. coli* and purified with Nickel
119 column and hydrophobic-interaction column. The SARS-CoV-2 RBD protein was expressed using
120 HEK293 cell and purified from cell supernatant using Protein A column.

121

122 **Chemiluminescence immuno-analysis (CLIA) for SARS-CoV-2 diagnosis**

123 Briefly, the purified NP or RBD viral antigens were coated onto magnetic particles for catching
124 SARS-CoV-2 specific IgA, IgM and IgG in sera. A second antibody that recognizes IgA, IgM or IgG
125 conjugated with acridinium (which can react with substrates to generate a strong chemiluminescence)
126 was used for detecting the IgA, IgM or IgG caught by antigen, respectively. The detected
127 chemiluminescent signal over background signal was calculated as relative light units (RLU). Such
128 collection contains all contents for CLIA of antigen-specific immunoglobulin is called kit here. Serum
129 samples were collected by centrifugation of whole blood in test tubes at room temperature for 15 min.
130 Prior to testing, serum samples were treated with a final concentration of 1% TNBP and 1% Triton
131 X-100 to completely denature any potential viruses[24]. Virus-inactivated sera were then diluted 40
132 times with dilution buffer and subjected to testing at room temperature. RLU was measured using a
133 fully automatic chemical luminescent immunoanalyzer, Kaeser 1000 (Kangrun Biotech, Guangzhou,
134 China).

135

136 **RBD-specific Antibody standards preparation**

137 SARS-CoV-2 RBD was immobilized to agarose beads by using *CNBr-activated Sepharose™ 4B*
138 reagent (GE Healthcare), then column filled with the RBD coupled agarose beads were employed to
139 purify RBD-specific IgA, IgM and IgG antibodies from a serum pool of recovering patients (a
140 manuscript in preparation). The concentrations of purified antibodies were determined using Bradford
141 method (using bovine serum albumin protein as a standard). These antibodies were used to make a
142 standard curve for each antibody detection to quantify the absolute antibody amounts in serum.

143

144 **Statistical analysis**

145 Receiver operating characteristic (ROC) analysis was conducted using MedCalc software to
146 determine the optimal cut-off value (criterion) and evaluate the diagnostic value of NP- or
147 RBD-specific IgA, IgM and IgG detection. The specificity and sensitivity of the antibody detection
148 were calculated according to the following formulas:

149 Specificity (%) = $100 \times [\text{True negative} / (\text{True Negative} + \text{False Positive})]$;

150 Sensitivity (%) = $100 \times [\text{True Positive} / (\text{True Positive} + \text{False Negative})]$;

151 Overall agreement (%) = $(\text{True negative} + \text{True Positive}) / \text{Total tests}$.

152 In order to analyze the correlation of serum antibody levels and age with disease severity, we first
153 used the Kruskal Wallis test[25] to test if there is any significant difference of antibody levels and age
154 among the three groups (Mild, Moderate, Severe). Then Dunn's test[26] was used to perform a
155 pair-wise test between each group, and Benjamini-Hochberg procedure[27] was used to adjust p-values.
156 All the above analyses used R software version 3.6.1[28]. A p value less than 0.05 was judged
157 statistically significant.

158

159 **Results**

160 **SARS-CoV-2 RBD is better than NP for COVID-19 diagnosis by antibody detection**

161 Highly purified SARS-CoV-2 NP and RBD proteins (**supplementary Figure 1**) were employed to
162 make a set of CLIA kits (hereinafter referred to as “kit”) for detecting the presence of NP- and
163 RBD-specific IgA, IgM and IgG, respectively. A cohort of 216 sera from 87 SARS-CoV-2 infected
164 patients together with 20 interfering sera as negative controls were tested by both NP and RBD kits.

165 ROC analysis was performed, the NP IgA, IgM and IgG kit showed diagnostic sensitivities of 89.8%,
166 78.2% and 95.8%, and specificities of 85.0%, 95.0% and 100% respectively (**Figure 1A-C**). However,
167 the RBD IgA, IgM and IgG kit showed higher diagnostic sensitivities of 97.2%, 93.1% and 96.8%, and
168 specificities of 100%, 90.0% and 100%, respectively (**Figure 1D-F**). We conclude that detection of
169 RBD-specific antibodies provide a better diagnostic accuracy than that of NP-specific antibody.

170

171 **Adding IgA to serological CLIA improves accuracy of SARS-CoV-2 diagnosis**

172 To further evaluate the diagnostic accuracy of the RBD-specific IgA, IgM and IgG kit, a total of 483
173 sera including 330 healthy sera, 138 interfering sera and 15 sera from once suspected cases were tested
174 as negative controls, respectively. Testing results were converted to scatter plots (**Figure 2A-C**),
175 RBD-specific IgA, IgM and IgG CLIA kit showed diagnostic sensitivities of 98.6%, 96.8% and 96.8%,
176 and specificities of 98.1%, 92.3% and 99.8%, respectively (**Figure 2D-F**). The sensitivities,
177 specificities and overall agreements of the RBD-specific IgA, IgM or IgG kit and their combinations
178 are also summarized (**Table 1**). When combining the of RBD IgA and IgG kit, the sensitivity,
179 specificity and overall agreement elevated to 99.1%, 100% and 99.7%, respectively, which was much
180 better than those when IgM and IgG kit were combined. IgA detection provides additional values for
181 COVID-19 diagnosis.

182 Data from 216 sera samples were divided into 6 groups according to the time windows of collection
183 after illness onset (**Table 2**). At 4-10 days after symptom onset, the RBD-specific IgA kit exhibited the
184 highest positive diagnostic rate as 88.2% (15/17), while IgM and IgG kit showed detection rates of
185 76.4% (13/17) and 64.7% (11/17), respectively. The 2 sera diagnosed as negative in the 4-10 days
186 group by IgA kit were collected at the 4th day after illness onset, which could be too early for detecting
187 viral-specific antibodies of any types. In the group of 11-41 days after symptom onset, both RBD IgA
188 and IgG kit showed the same positive diagnostic rate of 99.5% (198/199). In contrast, IgM kit
189 somehow showed a relatively lower positive diagnostic rate as 98.5% (196/199). These results suggest
190 that including IgA in a test provides better diagnostic outcome in early stage.

191

192 **False positive analysis demonstrates the RBD-based detection are highly specific to SARS-CoV-2**

193 When RBD-specific IgA, IgM or IgG individual kit was used, we observed a total of 9 (0.61% to
194 6.67%), 37 (5.54% to 40.0%) and 1 (0 to 0.73%) false positive cases in the three types of “negative
195 controls”, respectively (**Table 3**). IgA kit was worse than IgG kit in yielding 9 false positive, but much
196 better than IgM kit. Only one of the 9 cases who showed a weak positive signal (RLU was 38096) for
197 IgA also tested weak positive (RLU was 22701) for IgM, other eight cases were tested negative for
198 IgM and IgG kit. Except the only one case that was tested weak positive by IgA and IgM kit
199 simultaneously, all other “negative controls” who had a positive signal for one isotype of antibody kit
200 showed negativity for the rest of two other isotype antibody kit. Therefore, a combined test of using
201 IgA and IgG (+/- IgM) kits can identify few false positive samples that show a positive signal for just
202 one type of antibodies. The fact that very few cases of samples were IgA or IgG positive in 483
203 negative controls indicate that these RBD-based detection did not cross-interact with antibodies raised
204 against other human coronaviruses (presenting in ~15% of common cold cases and often causing
205 pneumonia). Taken together, our RBD based CLIA kits are highly specific to SARS-CoV-2.

206

207 **Kinetic studies of serum SARS-CoV2 RBD-specific IgA, IgM and IgG**

208 We analyzed the kinetics of all the three antibody isotypes when multiple serum samples were
209 collected from individual patients. Representative kinetic data from 9 COVID-19 patients was shown in
210 **supplementary Figure 2**. To better understand the trends of antibody levels in all of the 87 COVID-19
211 patients (some of them contributed multiple samples), we plotted the median RLU reading according
212 the time windows when sera were collected (**Figure 3A**), IgA detection show a highest sensitivity
213 during about 4 to 25 days after illness onset. Because the RLU reading would vary among IgA, IgM
214 and IgG due to different secondary antibodies used, we used highly purified RBD-specific IgA, IgM
215 and IgG proteins from pooled sera of COVID-19 patients as standards (**supplementary Figure 3**). In
216 this way, RLU reading was converted into absolute antibody concentration (amounts per mL). To
217 simplify a plot from large numbers of samples, we only plotted median with interquartile range values
218 of antibody concentrations vs. time windows. The median concentration of RBD-specific IgA reached
219 the peak (8.8 $\mu\text{g/mL}$) during 16 to 20 days after illness onset, and then began to decline but remained at
220 about 3.6 $\mu\text{g/mL}$ until 31-41 days (**Figure 3B**). The median concentration of RBD-specific IgG was the
221 lowest in early disease stages but raised at 15 days post illness onset, the IgG concentration reached its
222 peak during 21-25 days after illness onset as 16.5 $\mu\text{g/mL}$, and stayed at a relatively high concentration
223 (11.4 $\mu\text{g/mL}$) until 31-41 days (**Figure 3B**), suggesting that IgG is powerful for diagnostics at later
224 stages. Although IgM concentration reached its peak (7.25 $\mu\text{g/mL}$) at early stages, it was lower than
225 that of IgA or IgG. Our data suggest that IgM has the lowest diagnostic power among the three isotypes
226 of antibodies for diagnosing SARS-CoV-2. Adding IgA into a diagnosis that contains IgG and IgM
227 improves the serologic testing power at both early- and late-stage COVID-19.

228

229 **IgA as well as IgG and age positively correlated with COVID-19 severity**

230 To explore whether a simple laboratory test such as measuring RBD-specific antibody levels in
231 serum could serve as a quantifiable indicator for COVID-19 severity, we divided the 87 patients into
232 three severity groups based on established clinical classifications. Consistent with previous studies [29],
233 we found that disease severity was positively correlated with age in our cohort (**supplementary Figure**
234 **4**). Patients with severe symptoms were significantly older (median age of 62.5 years) than those
235 patients with moderate (median age of 46 years) and mild symptoms (median age of 30 years).
236 Remarkably, we found that IgA concentrations in severe cases were significantly higher than those
237 mild or moderate cases (**Figure 4A**). IgG levels in moderate and severe COVID-19 patients were also
238 higher than mild cases (**Figure 4C**), which was previously reported [9, 20].

239

240 **Discussion**

241 The nucleocapsid protein (NP) is the most abundant protein in coronaviruses, and often used as a
242 diagnostic marker for coronaviruses such as SARS-CoV[30]. The RBD is the ligand for receptor ACE2,
243 therefore RBD could be a main target for neutralization antibodies[31, 32]. Here, we explored the
244 possibility of using either NP or RBD as an immobilized antigen for developing a clinical COVID-19
245 diagnostic test. Our data (**Figure 1**) demonstrated RBD-based test is better than NP-based test. One
246 possible mechanisms of difference is that the NP antigen is expressed in bacteria, whereas the RBD
247 protein used here is expressed in a human cell line enabling critical glycosylation for high-affinity
248 binding to antibodies produced in COVID-19 patients.

249 When we combined our RBD-specific IgA and IgG kits together, the sensitivity, specificity and
250 overall agreement elevate to 99.1%, 100% and 99.7%, respectively (**Table 1**). Thus, our serological
251 tests have much higher accuracy than the current methods of detecting viral RNA (sensitivity < 70%)
252 [8-12], and published immune-assays such as “flow immunoassay” and ELISA in earlier studies [9-11,
253 16-20, 22, 23]. We revealed that both IgM and IgA had early responses, while IgG showed up later.
254 Rapid increase of the three isotypes of serum RBD-specific antibodies started at about 10 days after
255 illness onset (**supplementary Figure 2A-C**). The early appearance of IgA in COVID-19 patients' sera
256 is probably due to the initial infection of this virus at the respiratory system enriched with mucosal
257 immune cells. The low basal level of IgA in serum makes SARS-CoV-2 specific IgA detection highly
258 sensitive at early stage of infection. Therefore, IgA should be included in a serological test, which may
259 provide higher diagnostic accuracy for COVID-19.

260 When we analyzed IgA, IgM or IgG concentrations in the sera of patients with different severity, we
261 observed that disease severity was positively correlated with serum IgA concentrations (**Figure 4A**).
262 The underlying mechanisms of this novel observation need to be further investigated in the future. IgA
263 is traditionally recognized to play an anti-inflammatory role and prevent tissue damage at mucosal sites.
264 However, recent reports also demonstrated that serum IgA is involved in the formation of immune
265 complexes to amplify inflammatory responses[33]. Serum IgA induced proinflammatory cytokine
266 production by macrophages, monocytes and Kupffer cells in non-mucosal tissues including liver, skin
267 and peripheral blood[34]. The latter phenomenon indicates possible antibody-dependent enhancement
268 (ADE) of infection. The immunopathological effects of ADE have been observed in various viral
269 infections, characterized as antibody-mediated enhancement of viral entry and induction of a severe
270 inflammatory response[35]. It is unclear currently whether IgA as well as IgG contributed directly (e.g.
271 via ADE) or indirectly (e.g. leading to a pathogenic inflammatory storm[36]) to the worse clinical
272 outcome in severe COVID-19 patients. If so, blocking of IgA-Fc alpha Receptor I (Fc α RI, CD89, an
273 IgA receptor) interaction could mitigate ADE or inflammatory storms, thus providing a novel treatment
274 strategy.

275 The current study has several limitations. Serum samples were not available every day for each
276 patient, the earliest serum was collected at the 4th day, and last one was at the 41th day after
277 self-reported illness onset. There are only 17 cases of serum samples collected within the first 10 days
278 after illness onset; which consequently influenced the accuracy of early. Similarly, there were only 23
279 cases of serum samples taken after 30 days post illness onset, hampering an analysis of long-term
280 antibody levels in recovered patients. Most patients enrolled in this study were with clinically moderate
281 symptoms (56/87, 64.4%). There were 17 severe and 5 critical cases, respectively. There were also few
282 cases of mild COVID-19 patients. Therefore, this study of the correlation between antibody levels and
283 disease severity warrants further investigation.

284 In summary, this study reports a novel serological test for detecting SARS-CoV-2 RBD-specific IgA
285 as well as IgM and IgG for clinical diagnosis of COVID-19. Due to its high specificity and sensitivity,
286 this approach could sensitively and quantitatively measure levels of the three types of antibody in blood
287 and other tissues. The serological study also provides valuable information for monitoring
288 SARS-CoV-2 infection, understanding of COVID-19 pathogenesis and improving strategies for
289 preventing, treating and vaccine development of this pandemic disease.

290

291 **Acknowledgements**

292 We would like to thank the staff and patients at Department of Infectious Diseases, The First Affiliated
293 Hospital of USTC for their support in providing samples and clinical data collection. We would also
294 like to thank Profs. Jianping Weng and Tian Xue and other colleagues in Division of Life Sciences and
295 Medicine for their generous and professional support. We would like to thank Prof. Yan Xiang at
296 University of Texas Health Science Center at San Antonio for critical reading and comments on this
297 manuscript. We would specially thank Prof. Peihui Wang at Shandong University for a plasmid
298 expressing the SARS-CoV-2 spike protein.

299

300 **Authorship Contributions**

301 Tengchuan Jin, Yajuan Li and Xiaoling Ma provide funding, designed the study, participated in data
302 analysis, and wrote the manuscript. Huan Ma, Weihong Zeng and Hongliang He designed the study,
303 performed the majority of experiments, analyzed the data and drafted the manuscript. Other authors
304 participated in the experiments and/or writing of the manuscript.

305

306 **Conflict of Interest Disclosures**

307 Dehua Jiang, Weihuang He and Ruting Yi are employees of Kangrun Biotech LTD (Guangzhou,
308 China). Tengchuan Jin, Huan Ma, Weihong Zeng in USTC and Dehua Jiang have applied a joining
309 patent related to the antibody detecting kits. Other authors declare that they have no conflicts of
310 interest.

311

312 **Funding**

313 T.J. is supported by the Strategic Priority Research Program of the Chinese Academy of Sciences
314 (XDB29030104), National Natural Science Fund (Grant No.: 31870731 and U1732109), the
315 Fundamental Research Funds for the Central Universities (WK2070000108). TJ and XLM is supported
316 by a COVID-19 special task grant supported by Chinese Academy of Science Clinical Research
317 Hospital (Hefei) with Grant No. YD2070002017 and YD2070002001, respectively. M.H. is supported
318 by the new medical science fund of USTC (WK2070000130).

319

320 **References**

- 321 1. WHO. *Coronavirus disease 2019 (COVID-19) Situation Report – 47*. 07 March 2020;
322 Available from: <https://www.who.int/docs/default>.
- 323 2. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in
324 China, 2019. *N Engl J Med* 2020; **382**(8): 727-33.
- 325 3. Ksiazek TG, Erdman D, Goldsmith CS, et al. A novel coronavirus associated with severe
326 acute respiratory syndrome. *N Engl J Med* 2003; **348**(20): 1953-66.
- 327 4. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel
328 coronavirus from a man with pneumonia in Saudi Arabia. *N Engl J Med* 2012; **367**(19):
329 1814-20.
- 330 5. Bloomgarden ZT. Diabetes and COVID-19. *J Diabetes* 2020; **12**(4): 347-8.
- 331 6. Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by
332 real-time RT-PCR. *Euro Surveill* 2020; **25**(3), 2000045.

- 333 7. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel
334 coronavirus in Wuhan, China. *Lancet* 2020; **395**(10223): 497-506.
- 335 8. Tang Y-W, Schmitz JE, Persing DH, Stratton CW. The Laboratory Diagnosis of COVID-19
336 Infection: Current Issues and Challenges. *Journal of Clinical Microbiology* 2020. Published
337 online Apr 3. doi: 10.1128/JCM.00512-20.
- 338 9. Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in patients of novel
339 coronavirus disease 2019. *Clinical Infectious Diseases* 2020. Published online Mar 28. doi:
340 10.1093/cid/ciaa344.
- 341 10. Liu L, Liu W, Wang S, Zheng S. A preliminary study on serological assay for severe acute
342 respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients.
343 *medRxiv preprint* doi: <https://doi.org/10.1101/2020.03.06.20031856>.
- 344 11. Guo L, Ren L, Yang S, et al. Profiling early humoral response to diagnose novel coronavirus
345 disease (COVID-19). *Clinical Infectious Diseases* 2020. Published online 2020 Mar 21. doi:
346 10.1093/cid/ciaa310.
- 347 12. Lin C, Xiang J, Yan M, Li H, Huang S, Shen C. Comparison of throat swabs and sputum
348 specimens for viral nucleic acid detection in 52 cases of novel coronavirus (SARS-Cov-2)
349 infected pneumonia (COVID-19). *medRxiv preprint* doi:
350 <https://doi.org/10.1101/2020.02.21.20026187>.
- 351 13. Woo PC, Lau SK, Wong BH, et al. Detection of specific antibodies to severe acute respiratory
352 syndrome (SARS) coronavirus nucleocapsid protein for serodiagnosis of SARS coronavirus
353 pneumonia. *Journal of clinical microbiology* 2004; **42**(5): 2306-9.
- 354 14. Schroeder Jr HW, Cavacini L. Structure and function of immunoglobulins. *Journal of Allergy
355 and Clinical Immunology* 2010; **125**(2): S41-S52.
- 356 15. Boes M. Role of natural and immune IgM antibodies in immune responses. *Molecular
357 immunology* 2000; **37**(18): 1141-9.
- 358 16. Li Z, Yi Y, Luo X, et al. Development and Clinical Application of A Rapid IgM - IgG
359 Combined Antibody Test for SARS-CoV-2 Infection Diagnosis. *Journal of medical virology*
360 2020. Published online Feb 27. doi: 10.1002/jmv.25727.
- 361 17. Zhang W, Du R-H, Li B, et al. Molecular and serological investigation of 2019-nCoV infected
362 patients: implication of multiple shedding routes. *Emerging microbes & infections* 2020; **9**(1):
363 386-9.
- 364 18. To KK-W, Tsang OT-Y, Leung W-S, et al. Temporal profiles of viral load in posterior
365 oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2:
366 an observational cohort study. *The Lancet Infectious Diseases* 2020. Mar 23. pii:
367 S1473-3099(20)30196-1. doi: 10.1016/S1473-3099(20)30196-1.
- 368 19. Long Q-x, Deng H-j, Chen J, et al. Antibody responses to SARS-CoV-2 in COVID-19
369 patients: the perspective application of serological tests in clinical practice. *medRxiv preprint*
370 doi: <https://doi.org/10.1101/2020.03.18.20038018>.
- 371 20. Zhang B, Zhou X, Zhu C, et al. Immune phenotyping based on neutrophil-to-lymphocyte ratio
372 and IgG predicts disease severity and outcome for patients with COVID-19. *medRxiv preprint*
373 doi: <https://doi.org/10.1101/2020.03.12.20035048>.

- 374 21. Lamm ME. Interaction of antigens and antibodies at mucosal surfaces. *Annual review of*
375 *microbiology* 1997; **51**(1): 311-40.
- 376 22. Okba NM, Muller MA, Li W, et al. SARS-CoV-2 specific antibody responses in COVID-19
377 patients. *medRxiv* 2020. medRxiv preprint doi: <https://doi.org/10.1101/2020.03.18.20038059>.
- 378 23. Amanat F, Nguyen T, Chromikova V, et al. A serological assay to detect SARS-CoV-2
379 seroconversion in humans. *medRxiv preprint doi:*
380 *<https://doi.org/10.1101/2020.03.17.20037713>*.
- 381 24. Hellstern P, Solheim BG. The Use of Solvent/Detergent Treatment in Pathogen Reduction of
382 Plasma. *Transfus Med Hemother* 2011; **38**(1): 65-70.
- 383 25. Kruskal WH, Wallis WA. Use of ranks in one-criterion variance analysis. *Journal of the*
384 *American statistical Association* 1952; **47**(260): 583-621.
- 385 26. Dunn OJ. Multiple Comparisons Using Rank Sums. *Technometrics* 1964; **6**(3): 241-252.
- 386 27. Hochberg Y, Benjamini Y. More Powerful Procedures for Multiple Significance Testing. *Stat*
387 *Med* 1990; **9**(7): 811-8.
- 388 28. Team RC. R: A language and environment for statistical computing. R Foundation for
389 Statistical Computing, Vienna, Austria. 2019. <https://www.R-project.org/>.
- 390 29. Wolfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients
391 with COVID-2019. *Nature* 2020. Published online Apr 1. doi: 10.1038/s41586-020-2196-x.
- 392 30. Li Y-H, Li J, Liu X-E, et al. Detection of the nucleocapsid protein of severe acute respiratory
393 syndrome coronavirus in serum: comparison with results of other viral markers. 2005;
394 **130**(1-2): 45-50.
- 395 31. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of
396 SARS-CoV-2 by full-length human ACE2. *Science* 2020; **367**(6485): 1444-8.
- 397 32. Lan J, Ge J, Yu J, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to
398 the ACE2 receptor. *Nature* 2020. Published online Mar 30. doi: 10.1038/s41586-020-2180-5.
- 399 33. Hansen IS, Baeten DLP, den Dunnen J. The inflammatory function of human IgA. *Cellular*
400 *and molecular life sciences : CMLS* 2019; **76**(6): 1041-55.
- 401 34. Hansen IS, Hoepel W, Zaat SAJ, Baeten DLP, den Dunnen J. Serum IgA Immune Complexes
402 Promote Proinflammatory Cytokine Production by Human Macrophages, Monocytes, and
403 Kupffer Cells through Fc α RI-TLR Cross-Talk. *Journal of immunology* 2017; **199**(12):
404 4124-31
- 405 35. Cao X. COVID-19: immunopathology and its implications for therapy. *Nature Reviews*
406 *Immunology* 2020: 1-2.
- 407 36. Li G, Fan Y, Lai Y, et al. Coronavirus infections and immune responses. *Journal of medical*
408 *virology* 2020; **92**(4): 424-32.
- 409
410

411 **Tables**

412 **Table 1. Comparisons of sensitivity, specificity and overall agreements of RBD-specific IgA, IgM,**
413 **and IgG kit and their combinations for diagnosing SARS-CoV-2.**

Antibody type	Sensitivity		Specificity		Overall agreement	
	%	n/total	%	n/total	%	n/total
IgA	98.6	213/216	98.1	474/483	98.3	687/699
IgM	96.8	209/216	92.3	446/483	93.7	655/699
IgG	96.8	209/216	99.8	482/483	98.9	691/699
IgA and IgM	95.8	207/216	90.7	438/483	92.3	645/699
IgA and IgG	96.3	208/216	97.9	473/483	97.4	681/699
IgM and IgG	94.9	205/216	92.1	445/483	93.0	650/699
IgA and IgM and IgG	94.4	204/216	90.5	437/483	91.7	641/699
IgA or IgM	99.5	215/216	99.8	482/483	99.7	697/699
IgA or IgG	99.1	214/216	100	483/483	99.7	697/699
IgM or IgG	98.6	213/216	100	483/483	99.6	696/699
IgA or IgM or IgG	99.5	215/216	100	483/483	99.9	698/699

414

415

416

417

418 **Table 2. Sensitivity of RBD-specific IgA, IgM and IgG kits in serum samples obtained at different**
419 **periods after illness onset.**

Days after illness onset	Positive serum samples diagnosed by RBD-specific antibodies					
	IgA		IgM		IgG	
	%	n	%	n	%	n
4-10	88.24	15/17	76.47	13/17	64.71	11/17
11-15	100	30/30	100	30/30	96.67	29/30
16-20	100	55/55	100	55/55	100	55/55
21-25	98.21	55/56	100	56/56	100	56/56
26-30	100	35/35	100	35/35	100	35/35
31-41	100	23/23	86.96	20/23	100	23/23

420

421

422

423

424

425

426

427 **Table 3. Potentially false positive cases diagnosed by the current RBD-specific IgA, IgM and IgG**

428 **kits.**

Antibody type	False-positive cases					
	Healthy cases		Interfering cases		Once suspected cases	
	%	n	%	n	%	n
IgA	0.61	2/330	4.35	6/138	6.67	1/15
IgM	5.45	18/330	9.42	13/138	40.0	6/15
IgG	0	0/330	0.73	1/138	0	0/15

429 For IgA detection, two persons of 330 sera collected previously from obviously healthy donors showed

430 positive signals for no obvious reasons. For the interfering cases group who had various underlying

431 diseases, four of six “positive” detected by the RBD IgA kits included two patients who had kidney

432 disease and high-levels of self-antibodies, one had liver cirrhosis and another had breast cancer and

433 received chemotherapy. The one “false positive” sample in the once suspected cases group was a

434 breast cancer patient undergoing chemotherapy and had pneumonia.

435

436 **Figure legends**

437 **Figure 1. Comparison of NP- and RBD-based CLIA kits.** The receiver operating characteristic
438 (ROC) curve analysis for SARS-CoV-2 diagnosis by NP-specific IgA, IgM, and IgG kit (A, B, and C,
439 respectively), and RBD-specific IgA, IgM, and IgG kit (D, E, and F), respectively. Twenty interfering
440 sera and 216 sera from 87 SARS-CoV-2 infected patients were tested. AUC, area under the curve of
441 ROC.

442

443 **Figure 2. Testing results and diagnostic analysis of RBD-specific IgA, IgM and IgG kit.** Testing
444 results of RBD-specific IgA (A), IgM (B) and IgG (C) kit using 330 healthy sera, 138 interfering sera,
445 15 sera of once-suspected patients and 216 sera of 87 qPCR-confirmed COVID-19 patients. RLU:
446 relative light units. Black bar indicates median values. The dotted line indicates the cut-off value. D-F:
447 The receiver operating characteristic (ROC) curve analysis for SARS-CoV-2 diagnosis by the testing
448 results of RBD-specific IgA, IgM or IgG (D, E and F, respectively) using 483 sera of SARS-CoV-2
449 negative individuals and 216 sera of SARS-CoV-2 infected patients. AUC, area under the curve of
450 ROC.

451

452 **Figure 3. The kinetics of anti-RBD IgA, IgM and IgG levels in sera of COVID-19 patients at**
453 **different time windows.** The median values of RLU (A) or calculated antibody mass concentrations
454 (B) were plotted for each isotypes of three antibodies, IgA (red), IgM (green) and IgG (blue). Bars
455 indicate median with interquartile ranges.

456

457 **Figure 4. Serum antibody levels in three distinct severity groups of COVID-19 patients.** Mild: 25
458 sera from 9 patients; moderate: 135 sera from 56 patients; and severe: 56 sera from 22 patients. 5
459 critical patients were merged into the severe group. Antibody levels in serum samples were collected
460 from confirmed patients at 4 - 41 days post illness onset and presented as scatter plots. For IgA (A),
461 levels in mild, moderate and severe patients were sequentially increased (p values indicated). Results
462 for IgM are shown in B. For IgG (C), levels in moderate and severe patients were significantly higher
463 than mild patients.




Figure 1









Figure 2

A**B****Figure 3**

A**B****C****Figure 4**